 |
 |
Dear List Family.... (NOTE: I've been more than a bit distracted while writing this 'cause both kitties have been bouncing off the walls for the last coupla hours <groan>. Sooo please excuse typos that may have gotten by the spell checker) The following article had a disclaimer that was longer than the original document, and with apparent good reason! As I read it, they're saying - in VERY heavy-duty "PR-speak," they have high hopes for all of their "we-HOPE-it-works-but-haven't-done-ANY-human-based-studies-whatsoe ver-on-them-yet drug products!" In other words, this big press release is MOSTLY just "puffery" with lotsa "wind and smoke" added, UNLESS, that is, you happen to be a MONKEY! People, I'm concerned that new drug products in VERY early test-mode are being presented to us - the ill and desperate consumer - as tho this was a new shampoo or cosmetic that will make one look younger and be more desirable because, by golly, "it worked on our test-monkeys." Do we - the patients who will ultimately become the consumer of these "Madison-Avenueized" drugs want this kind of pre-human-trials sales build-up slung at us? Do we want our hopes built up to a near-fever pitch when these products are MANY years away from being available to US? Personally, I'd prefer NOT being treated like a starving rabbit being teased by having a carrot on a string dangled in front of me every few weeks. Barb Mallut [log in to unmask] -----Original Message----- From: janet marie paterson <[log in to unmask]> To: [log in to unmask] <[log in to unmask]> Date: Sunday, February 20, 2000 9:48 AM Subject: NEWS: PRESS RELEASE: Boston Life Sciences: Symptomatic Pd Improvement In Primates For Immediate Release BOSTON LIFE SCIENCES' NOVEL PARKINSON'S DISEASE THERAPEUTIC ACHIEVES SIGNIFICANT SYMPTOMATIC IMPROVEMENT IN PRIMATES Details of New Development Discussed at BIO CEO Conference in New York Boston, MA-February 17, 2000-Boston Life Sciences, Inc. (NASDAQ: BLSI) announced preliminary results of a primate study which demonstrated that the Company's lead therapeutic compound O-1369 significantly improved the symptoms of experimental Parkinson's Disease (PD). A summary of the results was announced at this week's BIO 2000 CEO & Investor Conference in New York. "The same scientific team that produced an apparent success with Altropane [registered trademakr] as a PD diagnostic has synthesized an extensive family of molecules that appear to meet structural and biological criteria to be effective therapies for PD," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "In preliminary studies in primates with experimentally induced PD, we have achieved an impressive degree of improvement in PD symptoms with our lead compound. In these studies, monkeys with mild to moderate PD were injected with either placebo or BLSI's O-1369. Movement was scored using vests containing computer chips to quantify the gross movements of the animals. "Prior to treatment, the monkeys had extremely low scores due to the rigidity of the induced PD. However, within one hour of drug injection, movement scores increased to normal. The animals exhibited quantitative and qualitative normal movement for up to 8 hours post-injection, and then reverted to their former rigidity. Sleep was not disturbed. "We will be testing this compound more extensively in PD and will be submitting the definitive results for publication following the completion of dose-optimization studies. "We believe that this compound represents a totally novel and very promising approach to the treatment of PD. Given the growing depth of our experience in the CNS area, our ultimate goal is to provide both reliable diagnosis and effective new therapies for Parkinson's Disease, ADHD and other CNS disorders," added Dr. Lanser. About Boston Life Sciences, Inc. Boston Life Sciences, Inc. is developing novel treatments for cancer, autoimmune disease, and central nervous system disorders. Products awaiting FDA review, in clinical trials or in preclinical development by BLSI include: Altropane, a radioimaging agent for the early diagnosis of Parkinson's Disease and Attention Deficit Hyperactivity Disorder; Troponin I as an anti-angiogenic treatment for cancer; AF-1 and Inosine for the potential treatment of stroke and spinal cord injury; Therafectin® for the treatment of rheumatoid arthritis; and transcription factors that may control expression of molecules associated with autoimmune disease and allergies. The foregoing contains certain forward-looking statements with regard to product development, which may not be realized due to the uncertainties inherent in the research and development and regulatory processes, as well as market conditions. # # # Statements made in this press release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include uncertainties associated with the results of human clinical trials, regulatory approval processes and other factors. The foregoing contains forward-looking statements with regard to product development, which may not be realized due to the uncertainties inherent in the research and development process, including applying laboratory results to the design and completion of clinical trials as well as the previously mentioned uncertainties. For further information, please contact: Media Jim Weinrebe, ext. 6650 Schwartz Communications 781.684.0770 Investors Maria Zapf Boston Life Sciences Investor Relations 617.425.0200 Boston Life Sciences, Inc. Marc Lanser, M.D. Chief Scientific Officer 617.425.0200 http://www.bostonlifesciences.com/news34.htm janet paterson 52 now / 41 dx / 37 onset a new voice: http://www.geocities.com/janet313/ 613 256 8340 PO Box 171 Almonte Ontario Canada K0A 1A0